Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Visionary Investigators Network

Neither a doctor nor a teaching hospital

Research payments

$20,571,519

1,275 payments

Through program year 2025, Visionary Investigators Network is reported as receiving $20,571,519 in research payments, across 1,275 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,552,177 196
2024 Research $4,757,801 224
2023 Research $4,294,949 125
2022 Research $3,092,962 106
2021 Research $2,178,623 93
2020 Research $1,911,740 115
2019 Research $1,783,267 416

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $14,570,874 195 payments
  2. Eisai Inc. $3,110,144 548 payments
  3. AbbVie, Inc. $923,116 105 payments
  4. Ucb SA $761,156 10 payments
  5. Novo Nordisk AS $305,224 121 payments
  6. Roche TCRC, Inc. $203,786 49 payments
  7. Allergan Inc. $185,223 43 payments
  8. Ipsen Innovation $130,259 139 payments
  9. Amneal Pharmaceuticals LLC $93,651 21 payments
  10. Argenx US, Inc. $92,118 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $3,407,351 18 payments
  2. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $2,281,622 13 payments
  3. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $2,221,671 135 payments
  4. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,295,176 4 payments
  5. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $1,260,896 10 payments
  6. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,008,014 2 payments
  7. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $983,462 4 payments
  8. Assessment of Safety, Tolerability, and Efficacy of Ly3372689 in Early Symptomatic Alzheimer's Disease $740,108 20 payments
  9. Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $628,221 4 payments
  10. A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease $533,214 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record